Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based therapy ... at the Keck Graduate Institute and its collaborators. The discovery has the potential ... published online on August 27 by Scientific Reports, an open access research journal ...
(Date:8/31/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... air emission abatement projects in North America ... for a municipality in the Southern USA ... that failed to meet the customer,s requirements. This demonstrates the value ... S. Webb , President and Chief Executive Officer.  ...
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Israel Biomedical Sensors Market - Growth, ... The Israel Biomedical Sensors market is ... of 3.73% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/31/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... scientific review has identified high value opportunities for ... patient need. Novogen is moving as quickly as ... entering into Phase 1 clinical trials with our ... Officer, Iain Ross , said that following ...
Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... , - German Chemical Parks ... The number of employees in German chemical parks ... In this same period, the number of,companies doing business at ... today by Dr. Klaus-Dieter Juszak, Chairman of the,German Sector Group ...
... EXPANSION INTO EUROPE AND STRENGTHENS ITS SENIOR MANAGEMENT ... 12 OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), ... for clinical trials, today announced that it has strengthened ... of Dr. Wolfgang Summa. As Executive Vice President, Europe ...
... today that it has acquired from biotechnology company Antisoma ... film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) ... United States for use as a second-line therapy to ... pleased to add Oforta to our existing oncology portfolio, ...
Cached Biology Technology:10,000 New Jobs, Investments Increased 210,000 New Jobs, Investments Increased 3OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 2OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 3Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 2Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 3
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Vitamin and mineral supplements can enhance mental energy and ... prone to anxiety and depression, according to a July ... Technologists (IFT) Annual Meeting & Food Expo held at ... faculty of medicine at the University of Calgary, Alberta, ...
... size and parental behavior are the key drivers in children,s ... the 2013 Institute of Food Technologists (IFT) Annual Meeting & ... crowd of more than 200 conference attendees heard new insights ... eating behaviors are and how the industry and parents can ...
... (OGL), New England Biolabs, Inc., and Northeastern University have reached ... tissue from the world,s most rare, strange, and remarkable ocean ... Ocean Genome Legacy , Founded in 2001 ... New England Biolabs, OGL is a non-profit environmental research organization ...
Cached Biology News:Taste rules for kids and healthy food choices 2Collection that may hold key to ocean's mysteries looks to expand in new waterfront home 2
... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... on one plate. The new ArraySlide 96 ... (7mm x 7mm) individual printing surfaces for ... analysis studies. Unlike other systems, this device ... presence of contaminating adhesives. The chamber itself ...
... chambers for sealing hybridization reactions on slides. The ... on a glass slide. Reaction solution is added ... are then sealed with plastic sealing dots. Dots ... of reaction fluid. These chambers enclose a 20 ...
Biology Products: